Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artificial intelligence-powered cloud security strategies for protecting critical clinical operations in healthcare environments.

Scientific reports·2026

Same author

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.

The Indian journal of tuberculosis·2026

Same author

Antidiabetic effects of <i>Gymnema sylvestre</i> and metformin co-therapy in a type 2 diabetic rat model.

World journal of experimental medicine·2026

Same author

Increased indolamine 2,3-dioxygenase activity in people with type 2 diabetes and comorbid depression.

The National medical journal of India·2026

Same author

Low-Dose Propranolol versus Amitriptyline for Episodic Migraine Prophylaxis: A Randomized Controlled Trial Assessing Efficacy, Safety, and Cost-Effectiveness.

Clinical drug investigation·2025

Same author

Prescribing trends of fixed-dose combination of domperidone and proton-pump inhibitor across tertiary care centers in India, is the combination rational?

Indian journal of pharmacology·2025

Search research articles

Related Experiment Video

Updated: May 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Biosimilars: current scientific and regulatory considerations.

Preeta Kaur Chugh, Vandana Roy¹

¹Department of Pharmacology, Vardhman Mahavir Medical College and Associated Safdarjung Hospital, House No. 73, G.F., Hemkunt Colony, Greater Kailash Part I, New Delhi 110048, India. docpreeta@yahoo.com.

Current Clinical Pharmacology

|August 20, 2013

Summary

This summary is machine-generated.

Biosimilars offer safe and effective treatment options for patients, comparable to original biologics. These therapies are crucial for making advanced treatments more accessible and affordable globally.

More Related Videos

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Related Experiment Videos

Last Updated: May 8, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Area of Science:

Biopharmaceutical development
Drug regulatory affairs
Immunology

Background:

Biologics are complex therapeutic proteins with unique manufacturing and immunogenicity profiles.
Patent expirations of innovator biologics create opportunities for the development of biosimilars.
Biosimilars are highly similar to their reference biologic products in quality, safety, and efficacy.

Purpose of the Study:

To review the clinical safety and regulatory landscape of biosimilars worldwide.
To highlight the potential of biosimilars in expanding patient access to advanced therapies.
To underscore the economic benefits of biosimilar adoption.

Main Methods:

Literature review of clinical safety data for biosimilars.
Analysis of global regulatory guidelines for biosimilar approval.
Comparative assessment of biosimilar and reference biologic characteristics.

Main Results:

Biosimilars demonstrate comparable clinical safety and efficacy to reference biologics.
Regulatory pathways for biosimilars are established in major global markets.
Significant cost savings are achievable through biosimilar utilization.

Conclusions:

Biosimilars represent a viable and safe therapeutic option for numerous conditions.
Harmonized regulatory approaches facilitate biosimilar development and market entry.
Widespread adoption of biosimilars promises substantial healthcare cost reductions and improved patient access.